Spinal Muscular Atrophy with Respiratory Distress 1 (SMARD1)
This information is for if your child has been recently diagnosed with SMARD1.
In this page, you will find information about:
- Symptoms, diagnosis and effects
- What causes SMARD1?
- Looking after your child
- Looking after yourself
- Support and resources
What is SMARD1?
SMARD1 is an inherited condition that causes muscle weakness and respiratory failure, usually beginning between the ages of 6 weeks and 6 months. SMARD1 is an extremely rare disease; the number of children affected is very small. Currently, it’s not possible to collect accurate numbers of those affected but this may change as knowledge of the condition increases.
In the UK, SMARD1 is sometimes also called:
- Distal Spinal Muscular Atrophy 1 (DSMA1)
- Distal Hereditary Motor Neuropathy Type VI (dHMN6 or HMN6)
What are its symptoms and effects?
Usually, the first and most noticeable symptom of SMARD1 is breathing difficulties (respiratory distress). This is caused by the diaphragm - the large, thin sheet of muscle separating the chest from the stomach that is essential for normal breathing - becoming paralysed. Along with this, and usually progressing rapidly after breathing difficulties start, there are signs of weakness in the muscles which are furthest from the centre of the body (distal muscles) - such as in the hands and feet. This weakness then spreads to all muscles, but within 2 years the muscle weakness usually stabilises. This is sometimes described as a ‘disease plateau’.
A child’s walking, crawling, arm and hand movement, head and neck movement and swallowing may all be affected, but the impact on each child varies. Some children may still have some ability to move their muscles while others lose all this ability. Other early symptoms of SMARD1 can include a weak cry and misshapen feet. For some children, fatty finger pads are another symptom.
SMARD1 may also affect nerves for sensation and control of body functions (the autonomic nervous system). This can lead to symptoms such as excessive sweating, an irregular heart rate or rhythm (cardiac arrhythmia), constipation, bladder incontinence and a reduced response to pain.
Sadly, life expectancy for babies who have SMARD1 is reduced. It’s difficult though to predict life expectancy for any individual child because the progression of SMARD1 varies between children, as does the use of appropriate medical interventions to support breathing.
What causes SMARD1?
Usually, nerve cells called lower motor neurons carry electrical signals from the brain to the muscles and make it possible to move them. In SMARD1, due to the changes in genetic material, the lower motor neurons degenerate which affects the link between the brain, the spinal cord and muscles. This means these muscles can no longer be stimulated, which causes them to waste or atrophy.
The affected gene in SMARD1 is:
- the IGHMBP2 gene (immunoglobulin mu-binding protein 2) found on chromosome 11q13.3
More than 60 different mutations in the IGHMBP2 gene have been found to cause SMARD1. Most of these affect either the amount or efficiency (functionality) of the IGHMBP2 protein produced by the IGHMBP2 gene.
Although the exact mechanism is unknown, if the IGHMBP2 protein isn’t working properly, or there isn’t enough of it, this leads to the degeneration of the lower motor neurons.
It’s thought that the amount of ‘functional’ protein the mutated IGHMBP2 gene produces may be linked to the severity of an individual’s SMARD1. The less functional IGHMBP2 protein a child has, the earlier they are likely to develop symptoms. However, many differences have been seen even between individuals who have identical changes in the IGHMBP2 gene, which suggests that other factors may also have an effect.
How is SMARD1 diagnosed?
As SMARD1 is a very rare condition, it sometimes doesn’t get recognised and it can take a very long time to get a diagnosis - perhaps several months. Sometimes it’s not possible to confirm the diagnosis.
It’s usually diagnosed following your child being in hospital with severe breathing difficulties. If doctors think this could be caused by SMARD1, a blood sample is taken for genetic testing to help confirm the diagnosis. They may ask for further tests, such as an electromyogram (EMG) or muscle biopsy if they’re still unsure.
Looking after your child
When your child’s diagnosis is confirmed, they may already be under the care of specialists in neuromuscular conditions and respiratory care. If not, you would expect to have a referral to these specialists so that you can meet to discuss next steps. Though families are prepared to travel, infants with SMARD1 may not cope well with a long journey so where this discussion takes place will very much depend on how well your child is and where the nearest specialist centre is.
Although there’s currently no treatment or cure for SMARD1, there are options to manage your child’s care so that they have the best possible quality of life and are as comfortable as possible. There’s a wide range of severity in SMARD1 so discussions will focus on the options most beneficial for your child.
At first these are likely to be of greatest concern as once a child with SMARD1 starts to show symptoms of severe breathing difficulties, they will need a lot of help to survive. This can involve the need for surgery to create an opening in their windpipe so that they can breathe through a tube rather than their mouth (a tracheostomy). This is a very big step and any family facing this option will have a full and careful discussion with their specialists as to whether this is best for their child.
Advance care plan
Though it’s a difficult discussion to have, it’s important that you have the earliest possible opportunity to discuss in-depth with your medical team the range of future care options that may be available so that they can record the treatment you do or don’t wish your child to have if their health deteriorates or in an emergency.
Who else may become involved in my child’s care?
As your child’s condition is complex and potentially life-threatening and affects you and all your family, you’ll need a lot of support from a number of different health professionals and the palliative care services. Palliative care includes the management of symptoms, information and practical support, and, if wanted, the provision of short breaks from caring for your child at home. The overall aim is to achieve the best quality of life for your child and to support you, whichever medical options are decided on.
If it’s possible for you to take your child home, some of the professionals may be based in your local hospital or children's hospice. As well as your child’s neuromuscular and respiratory specialists, your team may include specialists in:
- occupational therapy
- speech and language therapy
- community nursing
If you’re able to go home, you’ll need a great deal of practical support. A detailed ‘care package’ will be set up before your child is discharged from hospital. This often takes a long time to organise and is likely cover the following topics:
- Equipment and supplies
- Day and night-time carers / who will provide this service / hours and rotas
- Short breaks / respite care
- Procedures to cover emergencies
- Getting out and about - including play, leisure and education
- Sources of financial help
- Sources of support - including those in your local area
You should also receive information and advice about other financial, practical and emotional support available in your local area.
With your permission, your child’s emergency advance care plan can be shared with all the professionals supporting your child, including ambulance services, so that everyone is aware of your wishes. You should have your own copy so that you can give it to hospital services if you are away from your home area.
Your local children’s hospice services
Your local children’s hospice is there to support families, both practically and emotionally. They provide support and respite at any stage from diagnosis onwards. As well as offering nursing care, they provide a range of services that may include physiotherapy, complementary therapies, play and music therapy.
They can support you as you review and make decisions about your baby’s ongoing and future care should they become very unwell. They can also offer invaluable practical and emotional support and specialist care if, sadly, you are faced with the end of your child’s life. This may be within the hospice and in some areas in your own home.
Looking after yourself and your family
The impact of a diagnosis of SMARD1 on families is enormous. It often comes as a shock and you may experience feelings such as disbelief, confusion, anger and sadness. You may find it difficult to take everything or anything in.
Everyone’s different, but it’s important for you and your family to have access to emotional support and to have plenty of time to talk and ask questions. This can be with members of your child’s medical team, your local GP, health visitor, social worker, psychologist or a counsellor, family and friends, a spiritual leader, support groups, or online communities.
Even though you’ll be focused on your child, it’s important to try and look after yourself too. Things like remembering to keep your vaccinations up-to-date and getting the ‘flu’ jab. Perhaps ask friends and family to help out with practical jobs such as shopping and cleaning to help save you time and energy.
You may also benefit from accessing local short break services. These may be available in your home or at your children's hospice. Some local authorities also have residential short breaks provision for children with disabilities. You can ask your GP, community nurse, health visitor or social worker for more information.
A genetic counsellor is a healthcare professional who has expert training in genetics. They will explain how SMARD1 is inherited and what the chances are of other family members also being affected. Genetic counselling also provides the opportunity to discuss options and choices for any future pregnancies.
Following your child’s diagnosis, you should be offered genetic counselling. A referral to genetic services is usually made through your General Practitioner (GP), paediatrician or neurologist.
You may be eligible for a number of financial benefits to help towards the cost of providing the extra care your child needs. This does depend on your individual circumstances. For further information visit the website: www.gov.uk
Your health visitor, community nurse, neuromuscular care advisor, family support worker, social worker or outreach worker may be able to help with applications for financial benefits.
There are also a number of charities that can assist with the cost of general household goods, specialist equipment and holidays / days out.
Though there’s very limited research into SMARD1, what we do find out we report on this page.
Patient Registries are databases of genetic and clinical information about people with a particular condition. They provide points of contact for when new treatments develop that need to be tested in clinical trials. They also help specialists gain more knowledge about the condition and the number of people affected which helps to develop and improve worldwide standards of care for people with the condition.
Currently in the UK there isn’t a registry specifically for SMARD1. The UK SMA Patient Registry is mainly for people affected by SMA due to mutation in the SMN1 gene, however the registry does accept registrations from people affected by Spinal Muscular Atrophy with Respiratory Distress 1 (SMARD1) with mutation in the IGHMBP2 gene.
Support and Resources
Provide information and support to anyone in the UK affected by any form of SMA.
Together for Short Lives
Phone: 0808 8088 100
Provide information and support to families who have a child with a life-limiting condition.
Phone: 0808 808 3555
Provide information and support to families who have a child with a disability.
Author: SMA UK Information Production Team
Published: September 2018
Last updated: March 2019
Next full review due: September 2021
Eckart. M, Guenther. U, Idkowiak. J, Varon. R, Grolle. B, Boffi. P, Van Maldergem. L, Hubner. C, Schuelke.M, von Au. K (2012) The natural course of infantile spinal Muscular atrophy with respiratory distress type 1 (SMARD 1) Pediatrics 2012; 129;e148
van der Pol. WL et al 190th ENMC international workshop: Spinal muscular atrophy with respiratory distress/distal spinal muscular atrophy type 1 (2103) http://dx.doi.org/10.1016/j.nmd.2013.04.004 (accessed 20.08.18)
We are grateful to the writers and reviewers who assist us in our information production. A list of who this includes may be viewed on our website: www.smauk.org.uk/our-writers-and-reviewers-panel or requested from firstname.lastname@example.org
Whilst every effort is made to ensure that the information in this publication is complete, correct and up to date, this cannot be guaranteed and Spinal Muscular Atrophy UK shall not be liable whatsoever for any damages incurred as a result of its use. SMA UK does not necessarily endorse the services provided by the organisations listed in our information sheets.
If you have any feedback about this information, please let us know at: email@example.com